Therapeutic Response

MSI-H status confers therapeutic sensitivity to Nivolumab in patients with Colorectal Adenocarcinoma.

Statements

Source and description

Opdivo (nivolumab) [package insert]. FDA. The U.S. Food and Drug Administration (FDA) granted approval to nivolumab as a single agent for the treatment of adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.